Fact checked by Nick Blackmer Zepbound supports sustained weight loss for up to three years among adults with obesity and ...

Researchers at Mass General Brigham found that by December 2023, over one-third of all new prescriptions for type 2 diabetes ...

Novo Nordisk, the maker of Ozempic and Wegovy, has also jumped into the legal fight —this time by intervening in the OFA’s lawsuit against the FDA. The company supports the agency’s move to restrict ...

To what extent will health clinics go to keep selling in-demand weight-loss drugs now that the FDA has outlawed cheaper ...

When it comes to managing weight loss and type 2 diabetes with medications, research shows that it's out with the old and in ...

You may know about tirzepatide, also known as Mounjaro or Zepbound, due to its popularity for those looking to lose weight or treat diabetes. Now, researchers have gotten it approved to treat sleep ...

Eli Lilly's oral GLP-1 drug orforglipron showed strong Phase 3 results with 7.9% weight loss and good tolerability, ...

One man’s trash may be another man’s treasure, but dumpster diving when investing carries risks. You have to wade through a ...

The analyst highlights that Lilly’s drugs, Mounjaro and Zepbound, will likely keep gaining U.S. market share from Novo ...

The Ohio attorney general's office issues warning letters to more than a dozen medical spas across the state for misleading claims about compounded versions of Ozempic, Wegovy and Mounjaro.

Zepbound belongs to a class of drugs called dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist. It contains the active ingredient tirzepatide and comes ...

Tirzepatide and GLP-1 receptor agonists are replacing older treatments, marking a shift in how diabetes and weight loss are ...